Compare FirstEnergy Corp. (FE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? FirstEnergy Corp. trades at $48.58 (market cap $28.13B), while Vertex Pharmaceuticals Incorporated trades at $477.12 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.3× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays a 3.82% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| FE | VRTX | |
|---|---|---|
Market Cap | $28.13B | $121.09B |
Sector | Utilities | Health |
52-Week High | $51.91 | $529.59 |
52-Week Low | $40.30 | $366.54 |
Enterprise Value | $56.14B | $115.83B |
Dividend Yield | 3.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy Corp. (FE) trades at $49.17, down 0.1% on the day, with a bullish technical signal and strong analyst support. Recent earnings show mixed quarterly beats, while revenue growth is steady at $15.09 billion for 2025. The company benefits from rising data center demand and a $36 billion investment plan, highlighted by recent news of grid upgrades and leadership appointments to drive operational performance.
Outlook is positive with a consensus price target of $52.00, offering ~6% upside. Key opportunities include infrastructure investments and data center growth, but risks involve high debt levels and regulatory pressures. Institutional sentiment is bullish with no sell ratings, though net cash flow remains negative, requiring careful monitoring of capital expenditures.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
